Nurix Therapeutics (NASDAQ:NRIX) Research Coverage Started at UBS Group

UBS Group initiated coverage on shares of Nurix Therapeutics (NASDAQ:NRIX) in a research report released on Thursday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $35.00 target price on the stock.

Several other equities research analysts have also issued reports on the company. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 target price on shares of Nurix Therapeutics in a research report on Monday, October 21st. Oppenheimer lifted their price objective on shares of Nurix Therapeutics from $27.00 to $30.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 4th. Stephens reissued an “overweight” rating and set a $31.00 target price on shares of Nurix Therapeutics in a research report on Monday, October 14th. JPMorgan Chase & Co. lifted their price target on shares of Nurix Therapeutics from $31.00 to $34.00 and gave the stock an “overweight” rating in a report on Monday, July 15th. Finally, HC Wainwright upped their price objective on Nurix Therapeutics from $26.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, October 21st. One research analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company. Based on data from MarketBeat.com, Nurix Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $29.40.

Nurix Therapeutics Stock Performance

Nurix Therapeutics stock opened at $26.27 on Thursday. Nurix Therapeutics has a fifty-two week low of $4.22 and a fifty-two week high of $27.07. The firm’s 50-day simple moving average is $24.09 and its 200 day simple moving average is $19.98. The stock has a market cap of $1.29 billion, a PE ratio of -9.00 and a beta of 2.22.

Nurix Therapeutics (NASDAQ:NRIX) last announced its earnings results on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.67). The firm had revenue of $12.59 million for the quarter, compared to the consensus estimate of $13.85 million. Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. As a group, analysts predict that Nurix Therapeutics will post -2.84 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CFO Houte Hans Van sold 2,490 shares of the company’s stock in a transaction dated Tuesday, July 30th. The stock was sold at an average price of $20.67, for a total transaction of $51,468.30. Following the sale, the chief financial officer now directly owns 54,479 shares in the company, valued at $1,126,080.93. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, insider Christine Ring sold 3,290 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $25.00, for a total value of $82,250.00. Following the sale, the insider now owns 24,592 shares in the company, valued at approximately $614,800. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CFO Houte Hans Van sold 2,490 shares of Nurix Therapeutics stock in a transaction on Tuesday, July 30th. The shares were sold at an average price of $20.67, for a total value of $51,468.30. Following the sale, the chief financial officer now directly owns 54,479 shares of the company’s stock, valued at $1,126,080.93. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 63,105 shares of company stock valued at $1,507,181. Corporate insiders own 7.20% of the company’s stock.

Institutional Trading of Nurix Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Mirae Asset Global Investments Co. Ltd. increased its position in shares of Nurix Therapeutics by 31.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,330 shares of the company’s stock worth $54,000 after purchasing an additional 559 shares during the last quarter. GAMMA Investing LLC grew its stake in Nurix Therapeutics by 299.8% in the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock worth $95,000 after buying an additional 3,424 shares in the last quarter. International Assets Investment Management LLC increased its holdings in shares of Nurix Therapeutics by 1,098.4% in the 3rd quarter. International Assets Investment Management LLC now owns 4,494 shares of the company’s stock worth $101,000 after buying an additional 4,119 shares during the last quarter. EntryPoint Capital LLC purchased a new stake in shares of Nurix Therapeutics during the 1st quarter valued at $123,000. Finally, ProShare Advisors LLC lifted its holdings in shares of Nurix Therapeutics by 9.1% during the 1st quarter. ProShare Advisors LLC now owns 11,978 shares of the company’s stock worth $176,000 after acquiring an additional 998 shares during the last quarter.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.